Sean Lavin
Stock Analyst at BTIG
(3.06)
# 1,113
Out of 5,182 analysts
37
Total ratings
80%
Success rate
33.17%
Average return
Main Sectors:
Stocks Rated by Sean Lavin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TCMD Tactile Systems Technology | Downgrades: Neutral | n/a | $25.07 | - | 4 | Nov 5, 2024 | |
| PODD Insulet | Upgrades: Buy | $320 | $189.56 | +68.81% | 5 | Feb 3, 2022 | |
| MDT Medtronic | Downgrades: Neutral | n/a | $83.32 | - | 1 | Jan 10, 2022 | |
| ATRC AtriCure | Maintains: Buy | $42 → $48 | $29.28 | +63.93% | 3 | Feb 19, 2020 | |
| MASI Masimo | Downgrades: Neutral | n/a | $178.63 | - | 4 | Apr 16, 2019 | |
| HSDT Solana Company | Downgrades: Neutral | n/a | $2.16 | - | 4 | Apr 16, 2019 | |
| IRTC iRhythm Holdings | Upgrades: Buy | $80 | $122.35 | -34.61% | 3 | Apr 3, 2019 | |
| NEO NeoGenomics | Upgrades: Outperform | n/a | $8.29 | - | 4 | Apr 16, 2018 | |
| ABT Abbott Laboratories | Downgrades: Neutral | n/a | $91.13 | - | 1 | Jan 22, 2018 | |
| BSX Boston Scientific | Upgrades: Buy | n/a | $62.07 | - | 1 | Nov 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $61.57 | - | 3 | May 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $84.15 | - | 4 | Feb 2, 2017 |
Tactile Systems Technology
Nov 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $25.07
Upside: -
Insulet
Feb 3, 2022
Upgrades: Buy
Price Target: $320
Current: $189.56
Upside: +68.81%
Medtronic
Jan 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $83.32
Upside: -
AtriCure
Feb 19, 2020
Maintains: Buy
Price Target: $42 → $48
Current: $29.28
Upside: +63.93%
Masimo
Apr 16, 2019
Downgrades: Neutral
Price Target: n/a
Current: $178.63
Upside: -
Solana Company
Apr 16, 2019
Downgrades: Neutral
Price Target: n/a
Current: $2.16
Upside: -
iRhythm Holdings
Apr 3, 2019
Upgrades: Buy
Price Target: $80
Current: $122.35
Upside: -34.61%
NeoGenomics
Apr 16, 2018
Upgrades: Outperform
Price Target: n/a
Current: $8.29
Upside: -
Abbott Laboratories
Jan 22, 2018
Downgrades: Neutral
Price Target: n/a
Current: $91.13
Upside: -
Boston Scientific
Nov 30, 2017
Upgrades: Buy
Price Target: n/a
Current: $62.07
Upside: -
May 3, 2017
Downgrades: Neutral
Price Target: n/a
Current: $61.57
Upside: -
Feb 2, 2017
Downgrades: Neutral
Price Target: n/a
Current: $84.15
Upside: -